Erlonat — Erlotinib 100 mg
4397₴
5277₴
-17%
Erlonat 100 mg is a targeted therapy drug containing Erlotinib. Manufacturer: Natco Pharma (India). It is a generic version of Tarceva.
Mechanism of Action:
Erlonat is an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor. It inhibits the intracellular phosphorylation of EGFR, blocking the signaling pathway that drives cancer cell proliferation and survival.
✅ Specific Use: The 100 mg dosage is specifically optimized for Pancreatic Cancer regimens.
Indicated for the treatment of:
- Pancreatic Cancer: First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer (in combination with gemcitabine).
- Non-Small Cell Lung Cancer (NSCLC): Maintenance treatment or second/third-line treatment for metastatic NSCLC with EGFR activating mutations.
Standard Dose: Usually 100 mg daily for Pancreatic Cancer.
⚠️ ABSORPTION WARNINGS:
- 🚫 Take on an empty stomach. At least 1 hour before or 2 hours after the ingestion of food. Food dramatically increases bioavailability, leading to toxicity.
- 🚬 Smoking interaction: Smoking induces CYP1A2 enzymes, reducing drug levels by ~50%. Patients are advised to stop smoking.
- 💊 Acid Reducers: Avoid Proton Pump Inhibitors (PPIs like Omeprazole) as Erlonat requires stomach acid for absorption.
- Severe hepatic impairment.
- Pregnancy and breastfeeding (Category D).
- Hypersensitivity to erlotinib.
Common adverse events include:
- Rash (Acneiform dermatitis): Very common on face and chest. Often correlates with better clinical response/survival.
- Diarrhea: Can be severe; hydration and anti-diarrheal medication (Loperamide) may be needed.
- Dry skin and Paronychia (nail infection).
- Fatigue and loss of appetite.
100% original product
Delivery across Ukraine
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!